托法替布在加拿大类风湿关节炎患者中的有效性与安全性:一项前瞻性观察性研究的主要结果
加拿大托法替布治疗类风湿关节炎观察性研究(CANTORAL)为首次在加拿大开展的前瞻性观察性研究,纳入45个中心自2017年10月至2020年7月起始托法替布治疗的中重度类风湿关节炎患者504例。第6个月时52.9%和15.4%的患者分别达到CDAI定义的LDA和缓解,至第18个月疗效总体维持;治疗中出现的不良事件发生率为126.8/100患者年。
要点
- 第6个月52.9%患者达CDAI-LDA,15.4%达CDAI缓解,第3个月即有相似比例达标。
- 第3个月27.2%和41.7%患者分别达DAS28-ESR-LDA和DAS28-CRP<3.2,疗效维持至第18个月。
- 治疗中出现不良事件、严重不良事件和因不良事件停药的发生率分别为126.8、11.9和14.5/100患者年。
核心结论
- 托法替布在真实世界患者中与类风湿关节炎体征和症状的早期且持续改善相关。
- 有效性与安全性与托法替布已确立的临床特征一致。
研究设计与样本
- 加拿大托法替布治疗类风湿关节炎观察性研究(CANTORAL)为首次在加拿大开展的前瞻性观察性研究,评估托法替布在中重度类风湿关节炎中的有效性和安全性。
- 患者为2017年10月至2020年7月起始托法替布治疗者,来自45个加拿大中心,共504例,其中44.4%联合使用甲氨蝶呤。
- 共同主要结局为第6个月CDAI定义的LDA和缓解;次要结局至第18个月;安全性评估至第36个月。
主要发现
- 第6个月52.9%和15.4%的患者分别达到CDAI定义的LDA和缓解;第3个月(首次基线后评估)达标比例相似。
- 第3个月27.2%和41.7%的患者分别达到DAS28-ESR定义的LDA和DAS28-CRP<3.2;14.7%和25.8%分别达到DAS28-ESR缓解和DAS28-CRP<2.6。
- 第3个月轻度疼痛及中度(≥30%)和大幅(≥50%)疼痛改善的患者比例分别为29.6%、55.6%和42.9%。
- 第3个月19.9%和53.7%的患者分别达到HAQ DI评分大于或等于规范值和大于或等于MCID(≥0.22)。
- 结局总体维持至第18个月;治疗中出现不良事件、严重不良事件和因不良事件停药的发生率分别为126.8、11.9和14.5/100患者年,特别关注的不良事件不常见。
关键数值与推荐
- CDAI定义的LDA和缓解为共同主要结局(第6个月)。
- DAS28-ESR和DAS28-CRP定义的LDA和缓解、疼痛改善(VAS<20 mm为轻度疼痛;≥30%为中度改善;≥50%为大幅改善)、HAQ DI≥规范值(≤0.25)和≥MCID(≥0.22)为次要结局。
- 安全性评估至第36个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Canadian Tofacitinib for Rheumatoid Arthritis Observational (CANTORAL) is the first Canadian prospective, observational study assessing tofacitinib. The objective was to assess effectiveness and safety for moderate to severe rheumatoid arthritis (RA). Coprimary and secondary outcomes are reported from an interim analysis. METHODS: Patients initiating tofacitinib from October 2017 to July 2020 were enrolled from 45 Canadian sites. Coprimary outcomes (month 6) included the Clinical Disease Activity Index (CDAI)-defined low disease activity (LDA) and remission. Secondary outcomes (to month 18) included the CDAI and the 4-variable Disease Activity Score in 28 joints (DAS28) using the erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) level to define LDA and remission; the proportions of patients achieving mild pain (visual analog scale <20 mm), and moderate (≥30%) and substantial (≥50%) pain improvements; and the proportions of patients achieving a Health Assessment Questionnaire disability index (HAQ DI) score greater or equal to normative values (≤0.25) and a HAQ DI score greater or equal to minimum clinically important difference (MCID) (≥0.22). Safety was assessed to month 36. RESULTS: Of 504 patients initiating tofacitinib, 44.4% received concomitant methotrexate. At month 6, 52.9% and 15.4% of patients were in CDAI-defined LDA and remission, respectively; a similar proportion of patients achieved outcomes by month 3 (first post-baseline assessment). By month 3, 27.2% and 41.7% of patients, respectively, were in DAS28-ESR-defined LDA and DAS28-CRP <3.2; 14.7% and 25.8% achieved DAS28-ESR remission and DAS28-CRP <2.6. By month 3, mild pain and moderate and substantial pain improvements occurred in 29.6%, 55.6%, and 42.9% of patients, respectively; 19.9% and 53.7% of patients achieved a HAQ DI score greater than or equal to normative values and a HAQ DI score greater than or equal to MCID, respectively. Outcomes were generally maintained to month 18. Incidence rates (events per 100 patient-years) for treatment-emergent adverse events (AEs), serious AEs, and discontinuations due to AEs were 126.8, 11.9, and 14.5, respectively, and AEs of special interest were infrequent. CONCLUSION: Tofacitinib was associated with early and sustained improvement in RA signs and symptoms in real-world patients. Effectiveness and safety were consistent with the established tofacitinib clinical profile.
引用
- Haraoui B, Khraishi M, Choquette D, et al. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study. Arthritis Care Res (Hoboken). 2022. PMID: 35678771. doi:10.1002/acr.24966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。